---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-22-000006"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2022-01-28T23:59:59+00:00"
generated_at: "2026-06-27T14:19:35.727172+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Maravai acquires MyChem for $240M cash; expands ultra-pure nucleotides for mRNA therapeutics

## Summary
- Purchase price $240M cash at close plus contingent consideration based on future conditions.
- MyChem provides ultra-pure nucleotides for diagnostics, pharma, genomics; complements Maravai's TriLink mRNA technologies.
- MyChem to become part of TriLink's Nucleic Acid Production segment; founder-led team stays on.
- Deal strengthens Maravai's end-to-end mRNA supply chain and adds GMP manufacturing capability.
- Advisors: Jefferies & Kirkland & Ellis for Maravai; BroadOak & Morrison & Foerster for MyChem.

## SEC filing metadata
- accession: 0001823239-22-000006
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2022-01-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323922000006/0001823239-22-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323922000006/mrvi-20220128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-22-000006
- JSON: https://secwatch.observer/filing/0001823239-22-000006.json
- Plain text: https://secwatch.observer/filing/0001823239-22-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.